多剂量递增研究能否作为信息性概念验证研究
药物开发成本主要来自2期和3期,降低失败率可显著降低成本。本文提出一种基于模型的MAD设计,在关注安全性的同时,利用纵向剂量反应和剂量滴定影响的参数模型,为特定治疗领域的某些终点提供有效性数据,从而充当概念验证研究,可能缩短开发周期而不增加2期风险。
要点
- 基于模型的MAD设计可同时提供安全性和有效性信息
- 该设计可在2期前提供相对信息性的有效性数据
- 可能缩短药物开发周期而不增加2期开发风险
核心结论
- 基于模型的MAD设计可作为信息性概念验证研究,在2期前提供有效性数据,可能缩短开发周期而不增加2期风险。
研究设计与样本
- 本文提出一种基于模型的MAD设计,利用纵向剂量反应和剂量滴定对响应变量影响的参数模型。
主要发现
- 该MAD设计不仅提供所需的安全性信息,还能为特定治疗领域的某些终点提供信息性有效性数据。
临床怎么用
- 在特定治疗领域,可采用基于模型的MAD设计在2期前获取有效性数据,辅助决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Drug development is a long, complex, and costly process. The majority of the cost arises from Phase 2 and Phase 3 clinical development. Reducing Phase 2 and Phase 3 failure rates would greatly reduce the average drug development cost. Obtaining more informative data on a candidate drug's efficacy and safety prior to moving to Phase 2 will improve Phase 2 success and, hence, reduce the overall development cost. While, typically, multiple ascending dose (MAD) study focuses on safety, this article proposes a model-based MAD design that not only can provide the desired safety information but also can provide informative efficacy data for certain endpoints in certain therapeutic areas where the parametric models for the longitudinal dose response and the impact of dose titration on a response variable are utilized. This type of MAD design allows relatively informative efficacy data available prior to Phase 2 development and, hence, can serve as a proof-of-concept study. This approach may greatly reduce the drug development cycle time without increasing the risk of Phase 2 development.
引用
- Qu Y. Can a multiple ascending dose study serve as an informative proof-of-concept study? Stat Med. 2018. PMID: 30264404. doi:10.1002/sim.7982
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。